HIV immunotherapy comes of age: Implications for prevention, treatment and cure

Expert Review of Clinical Immunology

Volumn 12, Issue 2, 2016, Pages 91-94

  Routy, Jean Pierre ^a,b   Mehraj, Vikram ^b   Cao, Wei ^b,c  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Dendritic cell vaccine; HIV vaccine; Immune activation; Immunometabolism; Immunotherapy; Interleukin 21; Interleukin 7; Microbial translocation; T cell exhaustion

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL THERAPY; DISEASE COURSE; DRUG RESEARCH; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOTHERAPY; INFECTION PREVENTION; INFECTION RISK; MOLECULAR INTERACTION; NEOPLASM; REVIEW; RISK REDUCTION; TREATMENT PLANNING; ACQUIRED IMMUNODEFICIENCY SYNDROME; CD4+ T LYMPHOCYTE; FORECASTING; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; PHYSIOLOGY; PROCEDURES; TRENDS; VACCINATION; VIROLOGY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS VACCINES; CD4-POSITIVE T-LYMPHOCYTES; FORECASTING; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; VACCINATION;

EID: 84957433998     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2016.1112269     Document Type: Review

References (22)

1. Maartens G, Celum C, Lewin S.R. HIV infection: epidemiology, pathogenesis, treatment, and prevention. Lancet. 2014;384(9939):258-271. DOI:10. 1016/S0140-6736(14) 60164-1.
2. Rajasuriar R, Wright E, Lewin S.R. Impact of antiretroviral therapy (ART) timing on chronic immune activation/inflammation and end-organ damage. Curr Opin HIV AIDS. 2015;10(1):35-42. DOI:10. 1097/COH. 0000000000000118.
3. Burton DR, Mascola J.R. Antibody responses to envelope glycoproteins in HIV-1 infection. Nat Immunol. 2015;16 (6):571-576. DOI:10. 1038/ni. 3158.
4. Alter G, Sekaly RP. Beyond adjuvants: antagonizing inflammation to enhance vaccine immunity. Vaccine. 2015;33 (Suppl 2):B55-9. DOI:10. 1016/j. vaccine. 2015. 03. 058.
5. Burgener A, Sainsbury J, Plummer FA, et al. Systems biology-based approaches to understand HIV-exposed uninfected women. Curr HIV/AIDS Rep. 2010;7(2):53-59. DOI:10. 1007/s11904-010-0039-3.
6. Parsons MS, Boulet S, Song R, et al. Mind the gap: lack of association between KIR3DL1004/HLA-Bw4-induced natural killer cell function and protection from HIV infection. J Infect Dis. 2010;202(Suppl 3):S356-60. DOI:10. 1086/ 655966.
7. Jardine J, Julien JP, Menis S, et al. Rational HIV immunogen design to target specific germline B cell receptors. Science. 2013;340(6133):711-716. DOI:10. 1126/science. 1234150.
8. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009;361(23):2209-2220. DOI:10. 1056/NEJMoa0908492.
9. Williams WB, Liao HX, Moody MA, et al. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota crossreactive antibodies. Science. 2015. DOI:10. 1126/science. aab1253.
10. Balazs AB, Chen J, Hong CM, et al. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature. 2012;481(7379):81-84. DOI:10. 1038/ nature10660.
11. Hansen SG, Piatak M Jr., Ventura AB, et al. Immune clearance of highly pathogenic SIV infection. Nature. 2013;502 (7469):100-104. DOI:10. 1038/nature12519.
12. Dagenais-Lussier X, Mouna A, Routy JP, et al. Current topics in HIV-1 pathogenesis: the emergence of deregulated immuno-metabolism in HIV-infected subjects. Cytokine Growth Factor Rev. 2015. DOI:10. 1016/j. cytogfr. 2015. 09. 001.
13. Saez-Cirion A, Bacchus C, Hocqueloux L, et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI study. PLoS Pathog. 2013;9(3):e1003211. DOI:10. 1371/journal. ppat. 1003211.
14. Archin NM, Liberty AL, Kashuba AD, et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature. 2012;487(7408):482-485. DOI:10. 1038/nature11286.
15. Garcia F, Routy JP. Challenges in dendritic cells-based therapeutic vaccination in HIV-1 infection workshop in dendritic cell-based vaccine clinical trials in HIV-1. Vaccine. 2011;29 (38):6454-6463. DOI:10. 1016/j. vaccine. 2011. 07. 043.
16. Andres C, Plana M, Guardo AC, et al. HIV-1 reservoir dynamics after vaccination and antiretroviral therapy interruption are associated with dendritic cell-vaccine induced T-cell responses. J Virol. 2015. DOI:10. 1128/JVI. 01062-15.
17. Caskey M, Klein F, Lorenzi JC, et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature. 2015;522(7557):487-491. DOI:10. 1038/ nature14411.
18. Cao W, Mehraj V, Vyboh K, et al. Antiretroviral therapy in primary HIV-1 infection: influences on immune activation and gut mucosal barrier dysfunction. AIDS Rev. 2015;17 (3):135-146.
19. Zitvogel L, Galluzzi L, Kepp O, et al. Type I interferons in anticancer immunity. Nat Rev Immunol. 2015;15(7):405-414. DOI:10. 1038/nri3845.
20. Deeks SG, Autran B, et al. Towards an HIV cure: a global scientific strategy. Nat Rev Immunol. 2012;12(8):607-614. DOI:10. 1038/ nri3262.
21. Sereti I, Estes JD, Thompson WL, et al. Decreases in colonic and systemic inflammation in chronic HIV infection after IL-7 administration. PLoS Pathog. 2014;10(1):e1003890. DOI:10. 1371/journal. ppat. 1003890.
22. Ortiz AM, Klase ZA, Dinapoli SR, et al IL-21 and probiotic therapy improve Th17 frequencies, microbial translocation, and microbiome in ARV-treated, SIVinfected macaques. Mucosal Immunol. 2015. DOI:10. 1038/mi. 2015. 75.